18,105 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Acquired by Crestline Management LP

Crestline Management LP acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 18,105 shares of the biopharmaceutical company's stock, valued at approximately $595,000.

Other large investors also recently modified their holdings of the company. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth about $33,000. Wingate Wealth Advisors Inc. bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $53,000. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 1,587 shares in the last quarter. KBC Group NV grew its holdings in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 611 shares in the last quarter. Finally, AlphaQuest LLC grew its stake in Agios Pharmaceuticals by 106.2% in the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after purchasing an additional 2,338 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. Scotiabank decreased their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Finally, StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, May 10th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.00.

Agios Pharmaceuticals Trading Up 0.2%

Shares of AGIO traded up $0.06 during mid-day trading on Thursday, reaching $28.09. The company's stock had a trading volume of 177,736 shares, compared to its average volume of 694,267. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The stock has a market cap of $1.63 billion, a P/E ratio of 2.48 and a beta of 0.77. The business has a 50-day simple moving average of $28.94 and a two-hundred day simple moving average of $36.94.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. Research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.30% of the stock is currently owned by insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.